Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CKS1B | P61024 | 2/20 | 0.42 |
| ▸ | SKP1 | P63208 | 2/20 | 0.42 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 4/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776466 | 0.89 | MGLL (0.45) | MGLL | |
| SCHEMBL2964266 | 0.81 | ACHE (0.43) | ACHECKS1BSKP1SKP2SLC2A1 | |
| SCHEMBL2962388 | 0.79 | NAMPT (0.46) | ACHENAMPTCKS1BSKP1SKP2 | |
| SCHEMBL2960778 | 0.78 | DPP4 (0.51) | ACHECKS1BSKP1SKP2TLR9 | |
| SCHEMBL6409175 | 0.75 | ACHE (0.47) | ACHENAMPTCKS1BSKP1SKP2 | |
| SCHEMBL20897769 | 0.73 | HTR3A (0.62) | MGLL | |
| SCHEMBL13217691 | 0.72 | ACHE (0.49) | ACHENAMPTCKS1BSKP1SKP2 | |
| SCHEMBL5002349 | 0.72 | CHRM2 (0.53) | ACHEGPR119 | |
| SCHEMBL20767890 | 0.71 | NAMPT (0.64) | ACHENAMPTCKS1BSKP1SKP2 | |
| SCHEMBL13217682 | 0.70 | ACHE (0.45) | ACHENAMPTCKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-7772226-B2 | Condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-10 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | EISAI CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| US-20060100199-A1 | Novel condensed imidazole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060094722-A1 | Combination drug | EISAI CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| US-20060063787-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514552-A1 | NOVEL FUSED IMIDAZOLE DERIVATIVE | Eisai Co., Ltd. (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20040116328-A1 | Condensed imidazole derivatives | EISAI CO., LTD. (JP) | 2004-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219178-A1 | PREVENTIVE OR THERAPEUTIC AGENTS FOR MULTIPLE SCLEROSIS | MYT1, AQP4, AQP1 | ACHE 448/4885NAMPT 2426/4885CKS1B 2469/4885 |
| US-20060100199-A1 | Novel condensed imidazole derivatives | H1-2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-4 | ACHE 3509/4885NAMPT 3411/4885CKS1B 144/4885 |
| US-20060094722-A1 | Combination drug | DPP4, GLP1R, DPP7 | ACHE 3109/4885NAMPT 459/4885CKS1B 3049/4885 |
| US-20060063787-A1 | Condensed imidazole derivatives | DPP4, HDAC1, DPP7 | ACHE 832/4885NAMPT 2551/4885CKS1B 103/4885 |
| US-20090018331-A1 | CONDENSED IMIDAZOLE DERIVATIVES | DPP4, HDAC1, DPP7 | ACHE 832/4885NAMPT 2551/4885CKS1B 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.